Lupa Kata Sandi? Klik di Sini

atau Masuk melalui

Belum Memiliki Akun Daftar di Sini


atau Daftar melalui

Sudah Memiliki Akun Masuk di Sini

Konfirmasi Email

Kami telah mengirimkan link aktivasi melalui email ke rudihamdani@gmail.com.

Klik link aktivasi dan dapatkan akses membaca 2 artikel gratis non Laput di koran dan Majalah Tempo

Jika Anda tidak menerima email,
Kirimkan Lagi Sekarang

Kalbe Farma Inaugurates New Biological Drug Factory

Translator

Editor

27 January 2016 21:12 WIB

Workers of PT Kalbe Farma factory sort out medicine tablets in Cikarang, Indonesia West Java province. REUTERS/Enny Nuraheni

TEMPO.CO, Jakarta - PT Kalbe Farma (KLBF) inaugurates the development of its biological drug factory, PT Kalbio Global Medika in Cikarang, Bekasi, with an investment value that ranges between US$30 to US$35 million. The factory, which is built on a 10,000 meters square land, is predicted to begin production activity in Q2 2016.

"The development of the biological drug factory is Kalbe's follow-up to support the creation of an integrated pharmaceutical industry, from raw material, technology control, and attempt to increase export," Kalbe Farma CEO Irawati Setiady said on Wednesday, January 27, 2016.

The factory is built based on a joint-effort between Kalbe and a South Korean pharmaceutical company Genexine Inc. under a joint venture company PT Kalbe-Genexine Biologics. Kalbe owns 40 percent of the company's share, while the rest is owned by Genexine.

The factory will manufacture various bological drugs including vaccine, protein, and anti-body with an annual production capacity of 10.5 million syringe. "This will establish a strong foothold for the Indonesian pharmaceutical industry to win the business competition in ASEAN and global [market]," said Irawati.

PINGIT ARIA



BPOM Reveals Indications of Drug Crimes in Indonesia's Pharmaceutical Industry

17 November 2022

BPOM Reveals Indications of Drug Crimes in Indonesia's Pharmaceutical Industry

According to the BPOM chief, the aspect of drug control in Indonesia is not strong enough.


BPOM Finds Alleged Counterfeit Raw Ingredients of Medicinal Syrup

9 November 2022

BPOM Finds Alleged Counterfeit Raw Ingredients of Medicinal Syrup

Food and Drug Monitoring Agency (BPOM) reports new findings after investigating the source of the raw material for the solvent of medicinal syrups.


BPOM: Pharmacy Industry Also Responsible for Drug Safety Assurance

27 Oktober 2022

BPOM: Pharmacy Industry Also Responsible for Drug Safety Assurance

BPOM head Penny Lukito says the drug quality and safety system is not only the sole responsibility of her agency but also the pharmaceutical industry.


MPR Speaker Calls an End on Healthcare's Import Dependency

8 Juni 2021

MPR Speaker Calls an End on Healthcare's Import Dependency

MPR speaker Bambang Soesatyo urged the government to stop being dependent on imported healthcare and medical equipment.


Jokowi Calls for Health System Reform

5 November 2020

Jokowi Calls for Health System Reform

President Jokowi said that 90 percent of drug and raw materials still rely on imports, which was considered wasting foreign exchange.


A Long and Winding Road

23 Oktober 2020

A Long and Winding Road

Not all of Indonesia's biodiversity has been exploited to make natural medicines. Government subsidies must not be the determining factor.


Erick Thohir Calls For Research on Coronavirus Vaccine

5 Februari 2020

Erick Thohir Calls For Research on Coronavirus Vaccine

SOE Minister Erick Thohir was encouraging the state pharmaceutical industry to conduct research aiming to find the vaccine against the coronavirus.


Dishonest Doctors

14 November 2019

Dishonest Doctors

Collusion between doctors and pharmaceutical companies over the sale of medicines still continues.


Industry Ministry Aims at Rp130tn Investments in Three Sectors

4 Januari 2019

Industry Ministry Aims at Rp130tn Investments in Three Sectors

The Industry Ministry projected investment values for the chemical, pharmaceutical, and textile industries (IKFT) would reach Rp130 trillion in 2019.


Indofarma Seeks to Cut Rp93bn in Costs

3 Desember 2014

Indofarma Seeks to Cut Rp93bn in Costs

In a bid to cut operational costs,the state-owned pharmaceutical

company has trimmed down its number of managers from 38 people

to just 18.